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Scopolamine, an anticholinergic, is an attractive amnesic agent for discerning the action of candidate antiamnesic drugs. Bacopa
monniera Linn (Syn. Brahmi) is one such antiamnesic agent that is frequently used in the ancient Indian medical system. We
have earlier reported the reversal of diazepam-induced amnesia with B. monniera. In this study we wanted to test if scopolamine-
induced impairment of spatial memory can also be ameliorated by B. monniera using water maze mouse model. The objective of
study was to study the eﬀect of B. monniera on scopolamine-induced amnesia. We employed Morris water maze scale to test the
amnesic eﬀect of scopolamine and its reversal by B. monniera. Rotarod test was conducted to screen muscle coordination activity
of mice. Scopolamine signiﬁcantly impaired the acquisition and retrieval of memory producing both anterograde and retrograde
amnesia. Bacopa monniera extract was able to reverse both anterograde and retrograde amnesia. We propose that B. monniera’s
eﬀects on cholinergic system may be helpful for developing alternative therapeutic approaches for the treatment of Alzheimer’s
disease.
1.Introduction
The frequent causes of dementia include Alzheimer’s disease
(50%) [1]. Cognition deﬁcits produced by cholinergic antag-
onism mimic the cognitive symptomology of Alzheimer’s
disease [2]. Scopolamine, a muscarinic receptor antagonist,
is reported to impair Long term potentiation (LTP) [3],
and frequently used as amnesic agent for evaluation of anti-
amnesic eﬀect of new drugs. Considering the adverse eﬀects
of synthetic drugs [4, 5], there is search for natural remedies
which are safe and eﬀective. The World Health Organization
(WHO) estimates that 80% of the world’s population
presently uses herbal medicine for some aspects of primary
health care [6]. Therefore, natural products may provide a
new source of beneﬁcial neuropsychotropic drugs [5]p r o -
vided they are adequately tested and their mechanisms are
properly deciphered. Galantamine, a cholinesterase inhibitor
and isolated from Galanthus nivalis and Lycoris radiate [7, 8],
is useful for treatment of mild to moderate Alzheimer’s
disease [9, 10]. Bacopa monniera and Centella asiatica are
the main constituents of Indian Ayurvedic herbal medicine
which is known as Medhya rasayana. Centella asiatica is also
reported to improve memory and promote the neuronal
dendritic growth in hippocampus [11, 12]. The medicinal
eﬃcacy of B. monniera is also extensively reported in Indian
traditional literature such as Athar-Ved, Carak Samhita and
SusrutuSamhita.Ithasbeenextensivelyusedfortreatmentof
various neurological and neuropsychiatric diseases. Bacopa
monniera extract has been reported to improve the memory
in mice [13]. It contains bacosides A–F and nicotine as
an active constituent [14]. It improves the performance of
rats in various learning situations such as shock-motivated
brightness-discrimination reaction, an active conditioned
ﬂight reaction and the continuous avoidance response
[15]. Moreover, B. monniera also provides protection from
phenytoin (an antiepileptic drug)-induced cognition deﬁcit
[16]. Bacoside A is the prominent constituent of B. monniera
extract.Ithasbeenreportedtoalleviatetheamnesiceﬀectsof
scopolamine, neurotoxin and immobilization stress [17, 18].
Bacopa monniera improves the cognitive deﬁcit possibly by
exhibiting free radical scavenging and antilipid peroxidative
eﬀects [19]. There is evidence that the mechanism of2 Evidence-Based Complementary and Alternative Medicine
action of B. monneira c o u l db ea t t r i b u t e dt oac o m b i n a t i o n
of cholinergic modulation [20–24] and antioxidant eﬀects
[25–29]. Standardized extract of B. monniera was shown
to improve the logical memory, paired associated learning
and mental control in patients suﬀering from age-associated
memory impairment (AAMI) [30]. Calabrese et al. [31]
also demonstrated that B. monniera i sas a f ed r u go fc h o i c e
to enhance the cognitive performance in elderly person.
Chronic treatment of B. monniera also improves the cogni-
tive function in adult [22] and children [32, 33], suggesting
the usefulness of B. monniera in young community. In order
to evolve better candidates for cholinergic receptors with
minimal side eﬀects [34], we examined the antiamnesic
eﬀects of B. monniera on scopolamine-induced amnesia.
2. Methods
2.1. Animals. All experiments were performed in accordance
with the guidelines of Institute animal ethical committee and
European Communities Council Directive (86/609/EEC).
Adequate measures were taken to minimize pain or dis-
comfort with animal experimental procedures. Swiss albino
mice (male, age 3–5 months, weight 25–35g) were housed
four per cage with ad libitum access to food and water
under controlled laboratory conditions. Experiments were
conducted between 9:00 and 18:00h in a semi soundproof
laboratory. Healthy mice were screened on the basis of the
swimming ability and normal behavior. Rotarod test in
mice “before and after administration of scopolamine” was
used to validate muscle coordination activity of mice. Mice,
showing the normal fall time of 4min from rotating rod at
15 rpm speed were selected for memory evaluation (data not
shown).
2.2. Drugs and Chemicals. All the drugs solutions were
prepared before use. The standardized extract of B. monniera
(Lumen marketing company, Chennai), containing 55.35%
bacosides, was suspended in 5% Tween 80, while scopo-
lamine (Sigma-Aldrich, New Delhi) was dissolved in normal
saline.
2.3. Morris Water Maze. Morris water maze [35]w a su s e d
to assess learning and memory in experimental mice. There
are several advantages of Morris water maze over other
models of learning and memory [36] including absence of
motivational stimuli such as food and water deprivation,
electrical stimulations and buzzer sounds [37]. We followed
the methodology of Morris water maze described in our
earlier study. Brieﬂy, it consists of a circular water tank,
ﬁlled with opaque water, and one centimeter submerged
platform. During acquisition trial escape latency time (ELT),
time measure to locate the hidden platform, was noted
as an index of acquisition. Each animal was subjected to
the four acquisition trials per day for 6 consecutive days.
The time spent by the animal, searching for the missing
platform in target quadrant Q2 with respect to other
quadrant (Q1, Q3 and Q4) on 7th day was noted as an
index of retrieval. Rotarod test was performed to screen
the muscle coordination activity of mice before subjecting
them to water maze evaluation. Mice, showing abnormal
swimming pattern in water maze, coupled with low muscle
coordination activity in rotarod test were excluded from
study.Forstudyingtheeﬀectofdrugonacquisition,thedrug
solution was administered before acquisition trial for 6 days.
The diluent was administered before retrieval trial on 7th
day. In order to test the eﬀectof drug on retrievalof memory,
the drug solution was administered before retrieval trial on
7thday.Thestudywasdividedinelevengroups.Thenumber
ofmiceineachgroupwas7.Thedetailsofdrugtreatmentare
described in Table 1.
2.4. Data Analysis. All behavioral results were expressed as
mean + standard error of mean (SEM). We have analyzed
the behavioral results of Morris water maze using analysis
of variance (ANOVA) followed by post hoc “Dunnet’s”
test or least signiﬁcance diﬀerence (LSD) test. “a” indicates
signiﬁcance at P < .05 of particular day’s ELT (i.e., ELT of
Days 2–6) versus ELT on Day 1. We compared the ELT of
treated group with control’s ELT for each time point (i.e.,
Days 1–6). “b” indicates P < .05 versus ELT of control group
for the same day. We also compared the ELT of treated group
with ELT of 5% Tween 80 for each time point. “c” indicates
P < .05 versus ELT of 5% Tween 80 group for the same
day. The ELT of B. monniera treated group were compared
with scopolamine’s ELT for each time point. “d” indicates
signiﬁcance of ELT versus same day’s ELT of scopolamine
(0.5mgkg−1 oral) group. “e” indicates signiﬁcance of ELT
versus same day’s ELT of scopolamine (0.1mgkg−1 oral)
g r o u p .R e t r i e v a lt e s td a t aw e r ea n a l y z e db yA N O V Af o l l o w e d
by least signiﬁcance diﬀerence (LSD) test. “f” indicates P <
.05 versus time spent in other quadrants, that is, Q1, Q3 and
Q4.“g”indicatessigniﬁcanceatP<.05versuscontrolgroup’s
timespentintargetquadrant(Q2).“h”indicatessigniﬁcance
at P < .05 versus 5% Tween 80 group’s time spent in target
quadrant (Q2). “i” indicates signiﬁcance at P < .05 versus
scopolamine group’s time spent in target quadrant (Q2).
3. Results
3.1.ScopolamineImpairsAcquisitionandRetrievalofMemory.
Control mice showed gradual reduction in ELT with ongoing
acquisition trial (“a” indicates P < .05 versus ELT on day
1, F = 11.26) (Figures 1(a)–1(d)) .T h e s em i c es p e n tm o r e
time in target quadrant as compared to other quadrant
(“f” indicates P < .05 versus time spent in other quadrant,
F = 11.48) (Figures 2(a) and 2(b)). It indicates normal
acquisition and retrieval on control mice. 5% Tween 80
did not alter gradual decrease in ELT (Figures 1(a)–1(d))
and preferential stay of mice in target quadrant (Figures
2(a) and 2(b)) as compared to control. It suggested the
absence of per se eﬀect of 5% Tween 80 on acquisition
and retrieval. Similarly, standardized extract of B. monniera
(120mgkg−1 oral) alone neither enhanced nor impaired the
normal acquisition (Figure 1(a)) and retrieval (Figure 2(b))
as compared to control and 5% Tween 80 mice.
The higher doses of scopolamine 1.0 and 0.5mgkg−1
did not show gradual decrease in ELT. Similarly lower
doses 0.1mgkg−1 also did not gradually reduce the ELTEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Eﬀect of B. monniera on scopolamine-induced anterograde amnesia. In acquisition trials, each value represents mean ± SEM.
Control group shows signiﬁcant gradual reduction in escape latency time with acquisition days as compared with Day 1 ELT. “a” indicates
signiﬁcance at P < .05 of particular day’s ELT (i.e., ELT of Days 2–6) versus ELT on Day 1, here data were analyzed using one-way ANOVA
followed by Dunnett’s test. (a) 5% Tween 80 does not aﬀect normal acquisition as compared to control group. Similarly, B. monniera
(120mgkg−1 oral) does not aﬀect normal acquisition as compared to control group and Tween 80 group. (b) Scopolamine signiﬁcantly
impaired the gradual reduction in ELT with acquisition days at dose of 1, 0.5 and 0.1mgkg−1 as compared to control group and Tween 80
group. We compared the ELT of treated group with control’s ELT or 5% Tween 80 ELT in each time point (i.e., Days 1–6). “b” indicates P <
.05 versus ELT of control group for the same day. “c” indicates P < .05 versus ELT of 5% Tween 80 group for the same day. Here data were
analyzed by ANOVA followed by least signiﬁcance diﬀerence (LSD) test. (c) and (d) B. monniera (120mgkg−1 oral) signiﬁcantly attenuated
scopolamine (0.5 and 0.1mgkg−1)-induced impairment of decrease in ELT as compared with respective scopolamine-treated groups. We
compared the ELT of B. monniera-treated group with scopolamine’s ELT in each time point (i.e., Days 1–6). “d” indicates signiﬁcance of
ELT versus same day’s ELT of scopolamine (0.5mgkg−1 oral) group. “e” indicates signiﬁcance of ELT versus same day’s ELT of scopolamine
(0.1mgkg−1 oral) group. Here data were analyzed by ANOVA followed by LSD post hoc test.4 Evidence-Based Complementary and Alternative Medicine
Table 1: Regimen for administration of vehicle and pharmacological agents.
Treatment Group Figure
Administration of vehicle and pharmacological agents
Acquisition trials (Days
1–6) Retrieval trial (Day 7)
Control I (n = 7) Figures 1A–F, 2(a),
and 2(b)
NS (10mLkg−1 PO)
60min before + NS
(10mLkg−1 i.p.) 30min
before
NS (10mLkg−1 PO)
60min before + NS
(10mLkg−1 i.p.) 30min
before
5% Tween 80 per se II (n = 7) Figures 1A–F, 2(a),
and 2(b)
Tween 80 (10mLkg−1
P O )6 0m i nb e f o r e+N S
(10mLkg−1 i.p.) 30min
before
Tween 80 (10mLkg−1
P O )6 0m i nb e f o r e+N S
(10mLkg−1 i.p.) 30min
before
Scopolamine
anterograde III-V (n = 7/group) Figures 1(b)–1(d)
Tween 80 (10mLkg−1
P O )6 0m i nb e f o r e+S c o
(1mgkg−1 i.p.,
0.5mgkg−1 i.p.,
0.1mgkg−1 i.p.) 30min
before
Tween 80 (10mLkg−1
P O )6 0m i nb e f o r e+N S
(10mLkg−1 i.p.) 30min
before
Scopolamine
retrograde VI–VII (n = 7/group) Figure 2(b)
Tween 80 (10mLkg−1
P O )6 0m i nb e f o r e+N S
(10mLkg−1 i.p.) 30min
before
Tween 80 (10mLkg−1
P O )6 0m i nb e f o r e+S c o
(0.5mgkg−1 i.p.,
0.1mgkg−1 i.p.) 30min
before
Bacopa monniera +
Scopolamine 0.5
mganterograde
VIII (n = 7) Figure 2(b)
bm (120mgkg−1 PO)
60min before + Sco
(0.5mgkg−1 i.p.) 30min
before
Tween 80 (10mLkg−1
P O )6 0m i nb e f o r e+N S
(10mLkg−1 i.p.) 30min
before
Bacopa monniera +
Scopolamine 0.1
mganterograde
IX (n = 7) Figure 2(b)
BM (120mgkg−1 PO)
60min before + Sco
(0.1mgkg−1 i.p.) 30min
before
Tween 80 (10mLkg−1
P O )6 0m i nb e f o r e+N S
(10mLkg−1 i.p.) 30min
before
Bacopa monniera +
Scopolamine 0.5
mgretrogarde
X( n = 7) Figures 2E and F
Tween 80 (10mLkg−1
P O )6 0m i nb e f o r e+n s
(10mLkg−1 i.p.) 30min
before
BM (120mgkg−1 PO)
60min before + Sco
(0.5mgkg−1 i.p.) 30min
before
Bacopa
monniera−per se XI (n = 7) Figures 1(a), 2(b) BM (80mg,120mgkg−1
PO) 60min before
BM (80mg, 120mgkg−1
PO) 60min before
BM: Bacopa monniera standardized extract suspension in 5% Tween 80, NS: normal saline, n: number of mouse; Sco: scopolamine solution in normal saline;
Tween 80: 5% v/v Tween solution in normal saline.
with acquisition days, although the eﬀect was relatively
less intense than the higher doses of scopolamine due to
shift in ELT. These groups were signiﬁcantly diﬀerent from
control and 5% Tween 80 group (b = P < .05 and c =
P < .05, F values 1.01, 1.26, 2.89, 3.28, 8.4 and 16.38 on
Days 1–6 resp.) (Figure 1(b)). These mice also spent reduced
time in target quadrant (Q2) as compared to the control
mice when compared on 7th day with other quadrants
(Q1, Q3 and Q4) (data not shown). These observations
suggest that scopolamine impairs the process of acquisition
of new memory by producing anterograde amnesia which
subsequently aﬀects retrieval of memory implying lack of
acquisition.
For studying the eﬀect of scopolamine on retrieval
alone, scopolamine was administered before retrieval trial.
Scopolamine at 0.1mgkg−1 (intraperitoneal) i.p. dose did
n o tl o w e rt h et i m es p e n ti nt a r g e tq u a d r a n t( Figure 2(a))
where as at 0.5mgkg−1 i.p. it signiﬁcantly reduced the
t i m es p e n ti nt a r g e tq u a d r a n t( F i g u r e s2(a) and 2(b)) when
compared to the control group (“g” indicates P < .05, F
= 3.24) and 5% Tween 80 group (“h” indicates P < .05,
F = 3.24).
3.2. Bacopa monniera Attenuates Scopolamine-Induced Ante-
rograde Amnesia. Bacopa monniera at 120mgkg−1 oral (“a”
indicates P < .001 versus ELT on Day 1, F = 16.56) reversed
scopolamine (0.5mgkg−1 i.p.)-induced impairment of ELT
with ongoing acquisition trials (Figure 1(c))a sc o m p a r e d
with scopolamine (0.5mgkg−1 i.p.) group (“d” indicates P
< .05 versus the same day’s ELT of scopolamine group, F
values were 1.43, 5.38, 4.3, 4.56, 7.29 and 14.5 on Days 1–6
resp.). Bacopa monniera at 120mgkg−1 oral also attenuated
scopolamine (0.1mgkg−1 i.p.)-induced deﬁcit in decrease
in ELT with ongoing acquisition trials (Figure 1(d))a sEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Eﬀect of B. monniera on scopolamine-induced retrograde amnesia. During retrieval trials, each value represents mean ± SEM.
Control group shows signiﬁcant enhancement in time spent in target quadrant (Q2) as compared to other quadrant which suggests normal
retrievalofmemory.The5%Tween80doesnoalternormalretrievalsincethisgroupindicatesmoretimespentintargetquadrantthatisnot
diﬀerentfromcontrolgroup.(a)Scopolamineatdoseof0.5mgkg−1 i.p.,butnotat0.1mgkg−1 i.p.dose,signiﬁcantlyreducedthetimespent
in target quadrant by producing retrograde amnesia. (b) Bacopa monniera (120mgkg−1 oral) does not alter normal retrieval as compared
to control and 5% Tween 80. Bacopa monniera at 120mgkg−1 oral increases the time spent target quadrant in scopolamine treated mice as
compared to scopolamine alone treated mice and it, therefore, attenuates scopolamine (0.5mgkg−1 i.p.)-induced retrograde amnesia. “f”
indicates P < .05 versus time spent in other quadrants, that is, Q1, Q3 and Q4, here data were analyzed using one-way ANOVA followed by
Dunnett’s test. “g” indicates signiﬁcance at P < .05 versus control group’s time spent in target quadrant (Q2). “h” indicates signiﬁcance at P
< .05 versus 5% Tween 80 group’s time spent in target quadrant (Q2). “i” indicates signiﬁcance at P < .05 versus scopolamine group’s time
spent in target quadrant (Q2). Here, data were analyzed using one-way ANOVA followed by LSD test.
compared with scopolamine (0.1mgkg−1 i.p.) group (“e”
indicates P < .05 versus the same day’s ELT of scopolamine
group, F values 1.1, 1.26, 2.89, 3.28, 8.4, 16.38 on Days 1–6
resp.). Interestingly, B. monniera showed better antiamnesic
eﬀects with 0.1mgkg−1 i.p. dose of scopolamine. These mice
also spent more time in target quadrant (Q2) as compared
with scopolamine-treated amnesic mice during retrieval trial
(data not shown).6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Proposed schematic presentation of eﬀect of B. monniera on acquisition and retrieval of memory. The diagram depicts that
scopolamine-induced impairment of acquisition and retrieval of memory are reversed by B. monniera pretreatment.
3.3. Bacopa monniera Attenuates Scopolamine-Induced Re-
trograde Amnesia. Bacopa monniera (120mgkg−1 oral)
increased the scopolamine aﬀected mice in target quadrant
as compared with scopolamine-treated mice (“i” indi-
cates P < .05 versus scopolamine group’s time spent in
target quadrant, F = 3.24). Bacopa monniera attenuates
scopolamine (0.5mgkg−1 i.p.)-induced retrograde amnesia
(Figure 2(b)).
4. Discussion
Acetylcholine (ACh) is a neurotransmitter that has long
received much attention in memory research. Although the
eﬀects of ACh on memory have to be regarded separately
for the acquisition, consolidation, and recall phase and for
diﬀerent memory systems [38, 39], it remains a fact that
ACh acts on cholinergic receptors that are widely distributed
throughout in the brain. Cholinergic antagonism is reported
to produce cognition deﬁcit which imitates Alzheimer’s
disease [2] similar to hippocampal lesion-induced cognitive
deﬁcits [40, 41]. PSAPP mice, expressing the “Swedish” amy-
loid precursor protein and M146L presenilin-1 mutations,
are a well-characterized model for spontaneous amyloid
plaque formation. Bacopa monniera extract lowers A–β 1–40
and1–42levelsincortexandreversesY-mazeperformancein
PSAPPmice[24].Similarlyitalsoreducesβ-amyloidlevelsin
a doubly transgenic mouse model of rapid amyloid deposi-
tion (PSAPP mice) by reducing divalent metals, scavenging
the reactive oxygen species, decreasing the formation of lipid
peroxides and inhibiting lipoxygenase activity [23].
Scopolamine, acetylcholine receptor antagonist, is
reportedtoimpaircognitiveperformances[42–45]especially
spatial learning and memory [46,47]. It exerts amnesic eﬀect
equally in various behavioral models of memory including
Morris water maze [48–52]. Therefore, scopolamine is
considered as reliable tool to study antiamnesic eﬀects of
candidate molecules or extracts. Morris water maze model
represents the model of memory especially spatial memory.
During the acquisition trials, mouse locates the hidden
platform using spatial cues. It develops the spatial memory
on the basis of spatial arrangement of cues which helps in
locating the platform in subsequent trials. In this model,
the memory is developed progressively with repetitive
trials which resemble the human interactions. This model
is very helpful to analyze the reversal amnesic eﬀect with
investigational drug because receptive trials with ongoing
trials conﬁrm the progress of reversal of amnesia. Moreover,
it provides a clean validation platform for comparing the
ELT of test and control animals. In order to include the
homogenous population of normal mice, we have evaluated
the swimming ability of mice in water tank, and muscle
coordination in rotating road before performing MorrisEvidence-Based Complementary and Alternative Medicine 7
water maze test. It was selected for Morris water maze
test when it showed a good swimming ability and normal
amnesic mice, but also impairs the retrieval of trained
mice by producing retrograde amnesia. These ﬁndings are
supported by earlier studies where scopolamine induces
cognitive impairment in animal [47, 53]a n dh u m a n[ 54–
56]. It is excluded from the group of study if it did not
swim well or rapidly fall from rotating rod due to muscle
incoordination. In this study scopolamine signiﬁcantly
impaired the gradual decrease in ELT and subsequently
r e d u c e dt h et i m es p e n ti nt a r g e tq u a d r a n t( Q 2 )d u r i n g
retrieval trial in water maze tests. These observations suggest
that scopolamine not only impairs the process of acquisition
by producing anterograde amnesia, which subsequently
aﬀects the retrieval of these.
Bacopa monniera is known to attenuate amnesia [1,
21, 22, 36, 57–59]. In this study we used a suspension of
standardized extract powder of B. monniera, at 120mgkg−1
oral doses once daily. It is relatively less than non-
standardized powder or partial puriﬁed products. Bacopa
monniera shows its eﬀect upon longer treatment rather
than short treatment in humans. Therefore, B. monniera
was administered for 6 days before trials for antiamnesic
aﬀect. Our study utilized scopolamine model to evaluate
the antiamnesic eﬃcacy of B. monniera in consonance with
previous approaches [60–64].We report that B. monniera
able to reverse anterograde and retrograde amnesia induced
by scopolamine when administered orally. The proposed
scheme of eﬀect of B. monniera and scopolamine on acquisi-
tion and retrieval of memory is explained in Figure 3. This
ﬁnding is supported by earlier studies where B. monniera
extract [21]o ri t sc o n s t i t u t e s[ 65] shows similar eﬀects in
animal. Bacopa monniera with ginkgo biloba extract exerts
signiﬁcant anticholinesterase and antidementic properties
in mice and attenuates the scopolamine-induced cognition
deﬁcit in passive avoidance test [20] exhibiting cholinergic
characteristics [24] besides antioxidant [19, 25–27, 29, 66].
It also attenuates the spatial memory deﬁcit in rat model
of Alzheimer’s disease [67]. Hosamani and Muralidhara
reported the neuroprotective eﬃcacy of Bacopa monnieri
against rotenone-induced oxidative stress and neurotox-
icity in Drosophila melanogaster [68]. Bacopa monniera
is reported to reverse neurotoxin and colchicines-induced
depletion of acetyholine and suppression of choline esterase
activity and muscarinic receptor binding in frontal cortex
and hippocampus [17, 57]. Moreover, it is documented to
inhibit the acetyhcholine esterase activity dose dependently
[20]. Endogenous striatal acetylcholine is documented to
exert a positive modulatory action on N-methyl-d-aspartate
(NMDA) responses via muscarinic receptors [69]. Bacopa
monniera is reported to alter the expression of NR1 subunit
of NMDA receptor [70]. B. monnieri extract is reported
to reverse 5-HT2C receptor mediated motor dysfunction
in epilepsy by attenuating 5-HT content, 5-HT2C receptor
binding and gene expression in hippocampus of rats [71].
Scopolamine alters the gene expression of various
candidate molecules in rat hippocampus, which suggests
involvement of cholingergic system in LTP [72]. Several
studies strengthens the contribution of cholingergic system
for antiamnesic eﬀect of B. monniera in accordance with
earlier reports [20–22].
We were not able to ﬁnd any signiﬁcant eﬀect of B.
monniera per se on normal acquisition and retrieval of
memory. It suggests that B. monniera only reverses amnesia
but it does not improve the memory of normal animal. It
is our assumption that acute treatment could not increase
the memory beyond a certain threshold that already exists
in a system. Some studies have suggested that the choice
of dose and duration of B. monniera’s treatment is critical
for bringing its optimal eﬀects. The high doses of B.
monniera extract (∼50% of LD50) for 15 days demonstrates
anticonvulsant activity. When it administer acutely at [73]
lower doses (approaching 25% of LD50), anticonvulsant
activity is not observed [73]. It is possible that B. monniera
does not increase the memory after the acute or subchronic
treatment, while it alleviates the memory defects. It may
enhance the memory after long duration of treatment.
Bacopa monniera may not increase consolidation suﬃcient
to elicit a signiﬁcant improvement, although reversal of
amnesia may occur by elimination of interference of LTP.
On the basis of our ﬁndings, we can conclude that
scopolamine-induced amnesia may be mediated by cholin-
ergic system. Although the value of molecular analogs
needs more exploration in drug discovery, the potential of
traditional knowledge herbs such as B. monniera cannot
be underscored. It certainly needs deeper investigation,
particularly when the current reductionist approach has not
resulted in tangible therapies. These may include further
studies on downstream signaling mechanisms and other LTP
processes.
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